Russia facing shortages of certain insulins

3 April 2024

Russian patients with diabetes have been faced with serious difficulties in obtaining ultra-fast insulin aspart Fiasp from Denmark’s Novo Nordisk (NOV: N), reports The Pharma Letter’s local correspondent

In the first quarter of 2024, government purchases of the drug decreased by 95%, and it can no longer be found in pharmacies. Manufacturers explain the delays by increased demand.

According to data of the Russian analyst agency Headway Company, in January-March 2024 the overall government purchases of insulin aspart in Russia decreased by 70%, to 350.7 million roubles ($3.8 million) year-on-year. Of these, purchases of Fiasp from Novo Nordisk, (which was a leader in this market segment in the past), fell by 95%, to only 22 million roubles.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK